Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

pT0 Prostate Cancer: Predictive Clinicopathologic Features in an American Population.

Bream MJ, Dahmoush L, Brown JA.

Curr Urol. 2013 Aug;7(1):14-8. doi: 10.1159/000343546. Epub 2013 Jul 28.

2.

Can pT0 stage of prostate cancer be predicted before radical prostatectomy?

Descazeaud A, Zerbib M, Flam T, Vieillefond A, Debré B, Peyromaure M.

Eur Urol. 2006 Dec;50(6):1248-52; discussion 1253. Epub 2006 Jun 21.

PMID:
16828964
3.

Preoperative Clinical and Pathological Characteristics of pT0 Prostate Cancer in Radical Prostatectomy.

Park J, Jeong IG, Bang JK, Cho YM, Ro JY, Hong JH, Ahn H, Kim CS.

Korean J Urol. 2010 Jun;51(6):386-90. doi: 10.4111/kju.2010.51.6.386. Epub 2010 Jun 21.

4.

Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.

Mazzucchelli R, Barbisan F, Tagliabracci A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R.

Virchows Arch. 2007 Apr;450(4):371-8. Epub 2007 Feb 7.

5.

Stage pT0 after radical prostatectomy with previous positive biopsy sets: a multicenter study.

Bessède T, Soulié M, Mottet N, Rebillard X, Peyromaure M, Ravery V, Salomon L; Cancerology Committee of the French Urological Association.

J Urol. 2010 Mar;183(3):958-62. doi: 10.1016/j.juro.2009.11.016. Epub 2010 Jan 18.

PMID:
20083270
6.

[Nondetectable prostate cancer in radical prostatectomy specimens].

Murányi M, Morshed AS, Benyó M, Tóth C, Flaskó T.

Orv Hetil. 2012 Jan 22;153(3):113-7. doi: 10.1556/OH.2012.29285. Hungarian.

PMID:
22236417
7.

DNA comparison between operative and biopsy specimens to investigate stage pT0 after radical prostatectomy.

Bessede T, Girodon E, Allory Y, Le Floch A, Leroy K, Salomon L.

World J Urol. 2014 Aug;32(4):899-904. doi: 10.1007/s00345-014-1278-5. Epub 2014 Mar 27. Review.

PMID:
24671609
8.

Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy.

Köllermann J, Caprano J, Budde A, Weidenfeld H, Weidenfeld M, Hopfenmüller W, Helpap B.

Urology. 2003 Sep;62(3):476-80.

PMID:
12946750
9.
10.

Stage pT0 after radical prostatectomy: a diagnostic dilemma.

Schirrmacher S, Kallidonis P, Horn LC, Nenning H, Rassler J, Rai B, Do M, Liatsikos E, Stolzenburg JU.

World J Urol. 2015 Sep;33(9):1291-6. doi: 10.1007/s00345-014-1441-z. Epub 2014 Nov 23.

PMID:
25417181
11.
12.

Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men.

Eastham JA, Carver B, Katz J, Kattan MW.

Prostate. 2002 Mar 1;50(4):236-40.

PMID:
11870801
13.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

14.

Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.

Kadono Y, Yaegashi H, Izumi K, Ueno S, Kitagawa Y, Mizokami A, Asahi H, Kobashi K, Koshida K, Namiki M.

Anticancer Res. 2013 Mar;33(3):1147-51.

PMID:
23482794
15.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
16.

[Status and medicolegal implications in France pT0 stage of prostate cancer: a study by the CC-AFU].

Bessede T, Soulié M, Mottet N, Rebillard X, Peyromaure M, Ravery V, Salomon L; le sous-comité prostate du CC-AFU.

Prog Urol. 2012 Dec;22(16):1021-5. doi: 10.1016/j.purol.2012.07.018. Epub 2012 Sep 7. French.

PMID:
23178099
17.

No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.

Noguchi M, Noda S, Nakashima O, Kojiro M.

Oncol Rep. 2002 Sep-Oct;9(5):1075-80.

PMID:
12168076
18.

The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.

Joung JY, Kim JE, Kim SH, Seo HK, Chung J, Park WS, Hong EK, Lee KH.

BMC Urol. 2015 Aug 13;15:82. doi: 10.1186/s12894-015-0079-5.

19.

Finding of no tumor (pT0) in patients undergoing radical retropubic prostatectomy for clinically localized prostate cancer.

Prayer-Galetti T, Gardiman M, Sacco E, Fracalanza S, Betto G, Pinto F.

Anal Quant Cytol Histol. 2007 Apr;29(2):79-86.

PMID:
17484271
20.

Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr, Terris MK, Aronson WJ; Shared Equal Access Regional Cancer Hospital Database Study Group.

Urology. 2002 Oct;60(4):670-4.

PMID:
12385931

Supplemental Content

Support Center